1. |
Atkeson A, Yeh SY, Malhotra A, et al. Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis, 2009, 51(5): 351-362.
|
2. |
Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem, 1995, 270(22): 13076-13083.
|
3. |
Lee CG, Da SC, Dela CC, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol, 2011, 73: 479-501.
|
4. |
Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol, 2009, 8: 61.
|
5. |
Jafari B, Mohsenin V. Chitinase-3-like protein-1 (YKL-40) as a marker of endothelial dysfunction in obstructive sleep apnea. Sleep Med, 2016, 25: 87-92.
|
6. |
Li W, Yu Z, Jiang C. Association of serum YKL-40 with the presence and severity of obstructive sleep apnea syndrome. Lab Med, 2014, 45(3): 220-225.
|
7. |
Wang X, Xing GH. Serum YKL-40 concentrations are elevated and correlated with disease severity in patients with obstructive sleep apnea syndrome. Scand J Clin Lab Invest, 2014, 74(1): 74-78.
|
8. |
Bakirci EM, Unver E, Degirmenci H, et al. Serum YKL-40/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome. Turk Kardiyol Dern Ars, 2015, 43(4): 333-339.
|
9. |
Duru S, Yuce G, Firat H, et al. YKL-40: may be used as a new inflammatory biomarker in obstructive sleep apnea syndrome? Tuberk Toraks, 2015, 63(3): 158-164.
|
10. |
杭燕萍, 肖永龙, 张德平, 等. 阻塞性睡眠呼吸暂停低通气综合征患者血清 YKL-40 变化及其临床意义. 临床肺科杂志, 2011, 16(6): 857-859.
|
11. |
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation, 2004, 109(23 Suppl 1): I27-I32.
|
12. |
Lee CG, Elias JA. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol Res, 2010, 2(1): 20-27.
|
13. |
Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med, 2008, 358(16): 1682-1691.
|
14. |
Gomez JL, Crisafi GM, Holm CT, et al. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. J Allergy Clin Immunol, 2015, 136(1): 51-58.
|
15. |
Kjaergaard AD, Bojesen SE, Johansen JS, et al. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol, 2010, 68(5): 672-680.
|
16. |
Ridker PM, Chasman DI, Rose L, et al. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J Am Heart Assoc, 2014, 3(3): e897.
|
17. |
Harutyunyan M, Gotze JP, Winkel P, et al. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology, 2013, 218(7): 945-951.
|
18. |
Harutyunyan M, Christiansen M, Johansen JS, et al. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology, 2012, 217(6): 652-656.
|
19. |
Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet, 2005, 365(9464): 1046-1053.
|
20. |
Punjabi NM, Beamer BA, Jain A, et al. Elevated levels of neopterin in sleep-disordered breathing. Chest, 2007, 132(4): 1124-1130.
|